3 years ago

EAACI Guidelines on Allergen Immunotherapy: Hymenoptera venom allergy

Markus Ollert, Cezmi A Akdis, Hadar Zaman, Joanna N.G. Oude Elberink, Joanna Lange, Thilo Jakob, Otto Spranger, Franziska Ruëff, Ervin Mingomataj, Radoslaw Gawlik, Ronald van Ree, Betül Ayşe Sin, Constantinos Pitsios, Mitja Kosnik, M. Beatrice Bilò, Eva-Maria Varga, Susanne Halken, Giovanni B Pajno, Oliver Pfaar, Susanne Lau, Roy Gerth van Wijk, Graham Roberts, Marek Jutel, Stefania Arasi, Darío Antolín-Amérigo, Montserrat Fernandez-Rivas, Dermot Ryan, Gunter J Sturm, Antonella Muraro, Aziz Sheikh, Elizabeth Angier, Sangeeta Dhami, Ioana Agache, Dimitris I Mitsias, Moises A Calderón, Valerio Pravettoni, Ewa Cichocka-Jarosz, Holger Mosbech
Hymenoptera venom allergy is a potentially life-threatening allergic reaction following a honeybee, vespid or ant sting. Systemic allergic sting reactions have been reported in up to 7.5% of adults and up to 3.4% of children. They can be mild and restricted to the skin or moderate-to-severe with a risk of life-threatening anaphylaxis. Patients should carry an emergency kit containing an adrenaline autoinjector, H1-antihistamines, and corticosteroids depending on the severity of their previous sting reaction(s). The only treatment to prevent further systemic sting reactions is venom immunotherapy. This guideline has been prepared by the European Academy of Allergy and Clinical Immunology's (EAACI) Taskforce on Venom Immunotherapy as part of the EAACI Guidelines on Allergen Immunotherapy initiative. The guideline aims to provide evidence-based recommendations for the use of venom immunotherapy, has been informed by a formal systematic review and meta-analysis and produced using the Appraisal of Guidelines for Research and Evaluation (AGREE II) approach. The process included representation from a range of stakeholders. Venom immunotherapy is indicated in venom allergic children and adults to prevent further moderate to severe systemic sting reactions. Venom immunotherapy is also recommended in adults with only generalized skin reactions as it results in significant improvements in quality of life compared to carrying an adrenaline auto-injector. This guideline aims to give practical advice on performing venom immunotherapy. Key sections cover general considerations before initiating venom immunotherapy, evidence-based clinical recommendations, risk factors for adverse events and for relapse of systemic sting reaction, and a summary of gaps in the evidence. This article is protected by copyright. All rights reserved.

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1111/all.13262

You might also like
Never Miss Important Research

Researcher is an app designed by academics, for academics. Create a personalised feed in two minutes.
Choose from over 15,000 academics journals covering ten research areas then let Researcher deliver you papers tailored to your interests each day.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.